Dr. Sánchez-Juan is scientific director of the Valdecilla Biobank and Principal Investigator of the Dementia Research Group of University Hospital Marqués de Valdecilla at IDIVAL and CIBERNED. Dr. Sánchez-Juan specialized as a Neurologist at the Hospital Universitario Marqués de Valdecilla. After his residency he was awarded with the Wenceslao López Albo research grant. He spent a year as a researcher in Edinburgh at the Creutzfeldt Jakob National Surveillance Unit in the United Kingdom. Later he graduated in the field of Genetic Epidemiology at the Erasmus MC University (Rotterdam, The Netherlands), where he completed his MSc and PhD. During his stay in Rotterdam, he served as Coordinator of Prion Diseases Surveillance in the Netherlands and gained valuable experience in the field of epidemiology working in the prestigious Rotterdam Study cohort. In 2011 completed his clinical training as an expert in dementia and behavioural neurology at UCSF Memory and Aging Center in San Francisco. Dr Sánchez-Juan is author of more than 100 international publications indexed in Medline (h-index 21 Web of Science). The main scientific interest of Dr. Sánchez-Juan are neurodegenerative diseases, particularly prion diseases and Alzheimer's disease. His publications include first authorship in two genome-wide association studies on prion disease. He is also first or senior author of some pivotal highly cited articles in the field of prion diseases biomarkers, and he is the senior author of the current clinical diagnostic criteria for these diseases.

Dr. Russell Swerdlow is a professor in the Departments of Neurology, Molecular and Integrative Physiology, and Biochemistry and Molecular Biology at the University of Kansas School of Medicine. He directs the NIH-funded University of Kansas Alzheimer’s Disease Center, staffs the Kansas University Medical Center’s Memory Clinic, and directs the Kansas University Medical Center’s Neurodegenerative Disorders Program. He received his undergraduate and doctor of medicine degrees from New York University, and trained as a neurologist and Alzheimer’s specialist at the University of Virginia. He currently holds the Gene and Marge Sweeney Chair at the University of Kansas and is a recipient of an S. Weir Mitchell Award from the American Academy of Neurology, a Cotzias Award from the American Parkinson’s Disease Association, a Scholarly Research Award from the University of Kansas, and a Chancellor’s Club Research Award from the University of Kansas. He served as the Research Committee Chair of the CurePSP Foundation; Chaired the Commonwealth of Virginia’s Alzheimer’s Disease Commission; and is on the editorial board of several journals. Dr. Swerdlow’s research focuses on brain energy metabolism, the role brain energy metabolism plays in Alzheimer’s disease and other neurodegenerative diseases, and how to manipulate brain energy metabolism.

Gina Green- Harris, MBA Director, Center for Community Engagement and Health Partnerships Director, Wisconsin Alzheimer’s Institute- Regional Milwaukee Office Director, Lifecourse Initiative for Healthy Families (LIHF)- Regional Program Office UW-Madison School of Medicine and Public Health Gina Green-Harris provides leadership and governance to guide and build the capacity of the WAI Milwaukee office programs. She leads the outreach and research program in Milwaukee which is designed to provide resources and recruit minorities into research that is culturally specific to African- Americans. Since joining Institute the Milwaukee program has more than doubled the number of African Americans enrolled in the Wisconsin Registry for Alzheimer’s Prevention (WRAP). In addition, she was instrumental in collaboration between the University and Milwaukee Health Services, Inc (a federally Qualified Health Center) to establish a minority specific memory clinic in the heart of Milwaukee. This is the first of its kind and is being established as a national model for other FQHC’s to replicate. The Institute’s work is being followed by researchers across the state and nation to learn about their outreach and recruitment model. Ms. Green-Harris has served on local, state and federal boards and committees she is a member of the SMPH’s Equity and Diversity Committee and was recently appointed to the National Institute on Health’s National Think-tank for Community Engagement. She has a Bachelor of Science degree in Psychology from Central State University and a Master’s degree in Business Administration from Franklin University specializing in leadership coaching and team development. She has won several awards for her work and is an international speaker on leadership and Alzheimer’s disease. Ms. Green Harris believes that her current work is her ministry appointment. She spends lots of time working with her faith community and is a licensed minister. She is also a member of Delta Sigma Theta Sorority, Inc. Her motto in life is “meet the people where they are” and what she loves most about herself is that she never meets stranger.

Ralph Martins has dedicated the last 30 years to Alzheimer’s disease (AD) research during which he has been part of a number of ground-breaking discoveries including the seminal discovery of beta-amyloid, found in the brains of Alzheimer’s patients, which is now universally acknowledged as being fundamental to the molecular pathology of AD. He has successfully built a substantial and world-class research and clinical capacity in Western Australia with active links to international peers at the forefront of Alzheimer’s disease. He has led innumerable global collaborations facilitating international knowledge transfer. CI Martins was instrumental in co-leading the world's most comprehensive study towards developing an early diagnostic test for AD. This major national program entitled the Australian Imaging Biomarkers Lifestyle (AIBL) study of Ageing, which was a foremost multicentre prospective longitudinal study initiated in 2006, has brought together Australia’s leading researchers in Alzheimer’s disease in partnership with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) and places Australia at the forefront of the field globally. AIBL has been exceptionally successful in receiving recognition in some of the world’s leading scientific journals and has the support of some prominent research groups such as the U.S. Alzheimer’s Association and Alzheimer’s Australia. Upon the tremendous success of AIBL, CIA’s team is also attracting the attention of some of the world’s largest pharmaceutical companies such as Pfizer, GE Healthcare and Johnson & Johnson. Martins was instrumental in the establishment and foundation of the Cooperative Research Centre (CRC) for Mental Health, which duly secured $23 million in Australian Federal funding from 2011-2018, to investigate early detection and treatment of neurodegenerative diseases and psychoses. CIA has worked closely with peers in Sydney and Melbourne, who have collectively identified and now follow twenty pedigrees with dominantly inherited AD-causing mutations. The individuals from these pedigrees are participants of the Dominantly Inherited Alzheimer's Network (DIAN) study. The Clinical Trials Division of the McCusker Alzheimer's Research Foundation Inc, conducts numerous clinical trials (a number at Phases 2 and 3) evaluating the effectiveness of pharmaceutical agents being investigated as therapeutic agents for Alzheimer’s disease.

Dr. David Roalf is Research Assistant Professor of Behavioral Neuroscience in the Department of Psychiatry at the University of Pennsylvania. Dr. Roalf completed his PhD at Oregon Health & Science University in Portland, Oregon and completed a fellowship in Neuropsychiatry at the University of Pennsylvania. David is an Associate Fellow of the Institute on Aging at the University of Pennsylvania. His research studies involve Alzheimer’s disease, Parkinson’s disease and schizophrenia. His research has helped better define screening tools for dementia, including brief cognitive screening tools and the use of olfactory screening tests. David has been principal investigator on one research grant from the National Institute of Mental Health and NARSAD. He has published over 50 research papers and articles.

Dr. Rissman's work at UCSD is split into several parts that are balanced relatively equally. The goal of his basic science research is to discover novel biomarkers for neurodegenerative diseases with a specific focus on blood-based biomarkers. Of primary interest is the study of the biomarker utility and pathologic potential of neuronally-derived exosomes. Dr. Rissman's in vivo work is focused on the contribution of stress and changes in stress signaling intermediates in Alzheimer’s disease neuropathology and the discovery of compounds that impact the corticotropin-releasing factor system in Alzheimer's Disease. In addition to the research program, Dr. Rissman is the Director for the Alzheimer's Disease Cooperative Study (ADCS) Biomarker Core and the Neuropathology/Brain Bank for the Alzheimer’s Disease Research Center (ADRC) at UCSD. Both cores are comprised by wet laboratories and a biospecimen banks. Dr. Rissman is also the PI of UCSD’s Neuroplasticity of Aging Training Grant (T32) and teach graduate classes in the Neurobiology of Disease

Roberto Monastero is an Associate Professor in the Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Italy. Roberto Monastero completed his PhD at PhD in Physiopathology, University of Palermo. Research Interests • Epidemiology, psychology and genetic of dementia, Alzheimer’s disease and cognitive impairment in nondemented individuals • Epidemiology, psychology of Parkinson’s disease and parkinsonisms • Epidemiology and psychology of primary headache